176 related articles for article (PubMed ID: 29480328)
1. Ultra-early response assessment in lymphoma treatment: [
Mayerhoefer ME; Raderer M; Jaeger U; Staber P; Kiesewetter B; Senn D; Gallagher FA; Brindle K; Porpaczy E; Weber M; Berzaczy D; Simonitsch-Klupp I; Sillaber C; Skrabs C; Haug A
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):931-940. PubMed ID: 29480328
[TBL] [Abstract][Full Text] [Related]
2. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
3. Correlation between glycolytic activity on [18F]-FDG-PET and cell density on diffusion-weighted MRI in lymphoma at staging.
Giraudo C; Karanikas G; Weber M; Raderer M; Jaeger U; Simonitsch-Klupp I; Mayerhoefer ME
J Magn Reson Imaging; 2018 May; 47(5):1217-1226. PubMed ID: 29086453
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET/MR imaging of lymphoma nodal target lesions: Comparison of PET standardized uptake value (SUV) with MR apparent diffusion coefficient (ADC).
Bernstine H; Domachevsky L; Nidam M; Goldberg N; Abadi-Korek I; Shpilberg O; Groshar D
Medicine (Baltimore); 2018 Apr; 97(16):e0490. PubMed ID: 29668631
[TBL] [Abstract][Full Text] [Related]
5. Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients.
Atkinson W; Catana C; Abramson JS; Arabasz G; McDermott S; Catalano O; Muse V; Blake MA; Barnes J; Shelly M; Hochberg E; Rosen BR; Guimaraes AR
Abdom Radiol (NY); 2016 Jul; 41(7):1338-48. PubMed ID: 27315095
[TBL] [Abstract][Full Text] [Related]
6. Comparison of diffusion-weighted MRI and [
Morakote W; Baratto L; Ramasamy SK; Adams LC; Liang T; Sarrami AH; Daldrup-Link HE
Eur Radiol; 2024 Jan; 34(1):643-653. PubMed ID: 37542653
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 3T diffusion-weighted MRI and
Lee SY; Jee WH; Yoo IR; Jung JY; Im SA; Chung YG; Kang JH
Br J Radiol; 2019 Oct; 92(1102):20181051. PubMed ID: 31322913
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of combined MTV and ADC derived from baseline FDG PET/MRI in aggressive non-Hodgkins lymphoma.
Husby T; Johansen H; Bogsrud TV; Hustad KV; Evensen BV; Boellaard R; Giskeødegård GF; Fagerli UM; Eikenes L
BMC Cancer; 2022 Nov; 22(1):1117. PubMed ID: 36319985
[TBL] [Abstract][Full Text] [Related]
10. Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: comparison with 18F-FDG-PET.
Schwenzer NF; Schmidt H; Gatidis S; Brendle C; Müller M; Königsrainer I; Claussen CD; Pfannenberg AC; Schraml C
J Magn Reson Imaging; 2014 Nov; 40(5):1121-8. PubMed ID: 24923481
[TBL] [Abstract][Full Text] [Related]
11. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
12. Correlation between apparent diffusion coefficients and metabolic parameters in hypopharyngeal squamous cell carcinoma: A prospective study with integrated PET/MRI.
Zhang L; Song T; Meng Z; Huang C; Chen X; Lu J; Xian J
Eur J Radiol; 2020 Aug; 129():109070. PubMed ID: 32454330
[TBL] [Abstract][Full Text] [Related]
13. Utility of
Jitani AK; Dutta S; Mandal PK; De R; Jajodia E; Baul S; Chakrabarti P; Dolai TK
Indian J Med Res; 2021 May; 154(5):691-698. PubMed ID: 35532587
[TBL] [Abstract][Full Text] [Related]
14. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
[TBL] [Abstract][Full Text] [Related]
15. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
[TBL] [Abstract][Full Text] [Related]
16. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
Rakheja R; Chandarana H; DeMello L; Jackson K; Geppert C; Faul D; Glielmi C; Friedman KP
AJR Am J Roentgenol; 2013 Nov; 201(5):1115-9. PubMed ID: 24147485
[TBL] [Abstract][Full Text] [Related]
17. Correlation of mean apparent diffusion coefficient (ADC) and maximal standard uptake value (SUVmax) evaluated by diffusion-weighted MRI and 18F-FDG-PET/CT in children with Hodgkin lymphoma: a feasibility study.
Rosbach N; Fischer S; Koch V; Vogl TJ; Bochennek K; Lehrnbecher T; Mahmoudi S; Grünewald L; Grünwald F; Bernatz S
Radiol Oncol; 2023 Jun; 57(2):150-157. PubMed ID: 37341195
[TBL] [Abstract][Full Text] [Related]
18.
Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
[TBL] [Abstract][Full Text] [Related]
19. Does elevated glucose metabolism correlate with higher cell density in Neurofibromatosis type 1 associated peripheral nerve sheath tumors?
Berzaczy D; Mayerhoefer ME; Azizi AA; Haug AR; Senn D; Beitzke D; Weber M; Traub-Weidinger T
PLoS One; 2017; 12(12):e0189093. PubMed ID: 29206885
[TBL] [Abstract][Full Text] [Related]
20. Role of WB-MR/DWIBS compared to (18)F-FDG PET/CT in the therapy response assessment of lymphoma.
Maggialetti N; Ferrari C; Minoia C; Asabella AN; Ficco M; Loseto G; De Tullio G; de Fazio V; Calabrese A; Guarini A; Rubini G; Brunese L
Radiol Med; 2016 Feb; 121(2):132-43. PubMed ID: 26349573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
